Clinical trial
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With…
NCT00219596 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00219596 |
|---|---|
| Title | Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension |
| Official title | An 8-Week, Randomized, Open-Label, Parallel Group Study Comparing The Efficacy And Safety Of Xalacom With The Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glaucoma, Open Angle, Ocular Hypertension |
| Intervention type | Drug |
| Interventions | Xalacom, unfixed Latanoprost and Timolol |
| Enrollment | 240 |
| Start date | Jun 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Feb 18, 2021 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: